Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment

Y Wang¹, P Nangia-Makker¹, V Balan¹, V Hogan¹ and A Raz*,¹

Prostate cancer will develop chemoresistance following a period of chemotherapy. This is due, in part, to the acquisition of antiapoptotic properties by the cancer cells and, therefore, development of novel strategies for treatment is of critical need. Here, we attempt to clarify the role of the antiapoptotic molecule galectin-3 in prostate cancer cells using siRNA and antagonist approaches. The data showed that Gal-3 inhibition by siRNA or its antagonist GCS-100/modified citrus pectin (MCP) increased cisplatin-induced apoptosis of PC3 cells. Recent studies have indicated that cisplatin-induced apoptosis may be mediated by calpain, a calcium-dependent protease, as its activation leads to cleavage of androgen receptor into an androgen-independent isoform in prostate cancer cells. Thus, we examined whether calpain activation is associated with the Gal-3 function of regulating apoptosis. Here, we report that Gal-3 inhibition by siRNA or GCS-100/MCP enhances calpain activation, whereas Gal-3 overexpression inhibits it. Inhibition of calpain using its inhibitor and/or siRNA attenuated the proapoptotic effect of Gal-3 inhibition, suggesting that calpain activation may be a novel mechanism for the proapoptotic effect of Gal-3 inhibition. Thus, a paradigm shift for treating prostate cancer is suggested whereby a combination of a non-toxic anti-Gal-3 drug together with a toxic chemotherapeutic agent could serve as a novel therapeutic modality for chemoresistant prostate cancers.

Cell Death and Disease (2010) 1, e101; doi:10.1038/cddis.2010.79; published online 18 November 2010

Subject Category: Cancer

Prostate cancer is the most common cancer among men in Western countries. A large number of patients already show metastatic disease at the time of diagnosis. At this stage, prostate cancer is incurable and its growth can only be slowed by hormone deprivation or chemotherapy. Unfortunately, most cases eventually become hormone refractory and chemoresistant.¹ Therefore, it is important to understand the mechanisms for chemoresistance of prostate cancer, and discover new targets to retrigger the sensitivity of prostate cancer cells to chemotherapeutic drugs.

Galectin-3 (Gal-3), a 31 kD carbohydrate-binding protein, is involved in cell growth, cell adhesion, invasion, apoptosis and cancer cell metastasis.²⁻⁴ Increased expression of Gal-3 has been reported during the progression of several human tumors.⁵⁻⁷ In prostate cancer, Gal-3 protein expression may be decreased compared with normal prostate and prostatic intraepithelial neoplasia.⁸⁻⁹ Using differential immunohistochemistry, we recently reported that although the expression level of intact Gal-3 decreased, its cleavage could be associated with the progression of prostate cancer.¹⁰ Others have found that loss of Gal-3 expression in early stages of prostate cancer tissues and low aggressive prostate cancer cell lines was due to the heavy methylation of Gal-3 promoter.¹¹⁻¹² In addition, Gal-3 knockdown resulted in reduced cell invasion, cell proliferation, and tumorigenicity of PC3 cells.¹⁰ Resistance to apoptosis is one of the hallmarks of cancer cells. The antiapoptotic function of Gal-3 has been well demonstrated in a variety of human cancers, such as breast,¹³ ovarian,¹⁴ and bladder.¹⁵ However, data regarding the mode of action of Gal-3 in resistance to drug-induced apoptosis of human prostate cancer cells are not yet determined, as only a single study reported that overexpression of Gal-3 in Gal-3 null LNCaP cells resulted in the acquisition of resistance to anticancer drug-induced apoptosis.¹⁶ Another human prostate cancer cell line PC3, which is not sensitive to anticancer drugs, has high expression level of endogenous Gal-3. Therefore, we hypothesized that Gal-3 expression may contribute, in part, to the chemoresistance of prostate cancer, and that inhibition of Gal-3 using siRNA and/or its antagonist may salvage the sensitivity of prostate cancer cells to chemotherapy. GCS-100 AKA, modified citrus pectin (MCP), which is the pH-/temperature-modified form of citrus pectin (CP), is a highly complex branched polysaccharide rich in galactoside residues. CP is water insoluble and is unable to interact with Gal-3, but MCP is water soluble and acts as a ligand for Gal-3 competing with its association to natural ligands.¹⁷⁻¹⁹ It was reported that GSC-100/MCP could inhibit the lung colonization,¹⁷ cell–cell and cell–matrix interaction of B16-F1 melanoma cells.¹⁸ Oral intake of MCP could inhibit the lung metastasis of prostate cancer cells in rat.¹⁹ GCS-100/MCP feeding inhibited the tumor growth, angiogenesis, and spontaneous metastasis of human breast and colon carcinoma cells in nude mice.¹⁰ Jackson et al reported that MCP induced apoptosis in human prostate cancer cells.¹¹ It was

¹Department of Pathology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
*Corresponding author: A Raz, Department of Pathology, Tumor Progression and Metastasis, Karmanos Cancer Institute, School of Medicine, Wayne State University, 110 East Warren Ave, Detroit, MI 48201, USA. Tel: 313-578-4330; Fax: 313-831-7518; E-mail: raza@karmanos.org

Keywords: calpain; galectin-3; MCP; prostate cancer; apoptosis

Abbreviations: Gal-3, galectin-3; MCP, modified citrus pectin; CP, citrus pectin; PARP, poly (ADP-ribose) polymerase; SDS, sodium dodecyl sulfate; HBSS, Hanks’ balanced salt solution; BSA, bovine serum albumin

Received 18.5.10; revised 10.9.10; accepted 11.10.10; Edited by D Bano
also shown that GCS-100/MCP either alone or in combination with dexamethasone inhibits myeloma cells growth, and overcomes drug resistance.22

Cisplatin, a widely used chemotherapeutic agent, is highly effective against several cancers, including testicular, breast, ovarian, bladder, and lung cancers. Late stage prostate cancer is resistant to cisplatin treatment because of the development of chemoresistance.23 Cisplatin treatment in Gal-3-expressing PC3 cells could serve as a model to study the relationship between Gal-3 expression and chemoresistance of prostate cancer cells. Two major apoptotic pathways have been defined: death receptor apoptotic pathway leading to caspase-8 activation and mitochondrial apoptotic pathway leading to cytochrome c release and caspase-9 activation.24

Both pathways activate downstream effector caspasases (caspase-3, -6, and -7) that lead to apoptosis features. Of note, in prostate cancer, it was reported that apoptosis can be mediated by calpain activation.25,26 Calpain is a family of calcium-dependent proteases, calpain 1 and 2 are major family members. Studies suggest that apoptosis may be mediated by calpain activation in response to the alteration of mitochondria-mediated calcium homeostasis.27 Calpain activation may lead to the cleavage of androgen receptor into an androgen-independent isoform in apoptotic prostate cancer cells.28 Here, we report that inhibition of Gal-3 using siRNA or its antagonist GCS-100/MCP increased cisplatin-induced apoptosis of PC3 cells, and calpain activation contributed to the proapoptotic effect of Gal-3 inhibition.

Results

Gal-3 knockdown sensitized PC3 cells to chemotherapy drug-induced apoptosis. RNAi technique was used to knockdown Gal-3 expression, and the expression levels of Gal-3 protein in two transfectants were sharply reduced (Figure 1a). Furthermore, the lower panel shows that Gal-3 protein mainly localized in the cytoplasm of PC3 cells. Figure 1b shows that Gal-3 knockdown boosts apoptosis of PC3 cells treated by 50 μM of cisplatin or 6 nM of docetaxel. The proapoptotic effect of Gal-3 knockdown was further confirmed by detection of 89 kD poly (ADP-ribose) polymerase (PARP). DNA laddering assay, cell viability assay, and DNA content assay by flow cytometry. PARP, a 113 kD protein, is cleaved to fragments of ~89 and 24 kD during apoptosis,29 and detection of 89 kD PARP has served as a marker of apoptosis.30 As shown in Figure 1c, compared with VC cells, significantly increased levels of 89 kD PARP were detected in siGal3-11 and siGal3-19 after cisplatin treatment. Figure 1d shows more DNA fragmentation was detected in Gal-3 knockdown cells after cisplatin treatment. Cell viability assay also showed that fewer cells survived in siGal3-11 (40% ± 3.6) and siGal3-19 (26.6% ± 4.5) clones compared with VC cells (53.8% ± 5.8) after cisplatin treatment (Figure 1e). In Figure 1f, cisplatin treatment resulted in more sub-G1 region cells, indicating more apoptotic cells in Gal-3 knockdown clones.

Gal-3 knockdown potentiated cisplatin-induced caspase activation. Western blot analysis of the expression of active caspase-3 (Figure 2ai) and caspase-3 activity assay (Figure 2aii) suggested that Gal-3 knockdown transfectants showed a higher level of caspase-3 activation than control cells after cisplatin treatment. As shown in Figure 2b, cisplatin treatment resulted in caspase-9 activation in Gal-3 knockdown transfectants, but no caspase-9 activation was observed in control cells. The expression of Gal-3 protein is not changed by cisplatin treatment (Figure 2c).

Gal-3 knockdown facilitated mitochondrial apoptotic events. Mitochondria were stained with mitochondrion-selective probe MitoTracker Red CMXRos. As observed in untreated cells (Figures 3A, a, b, and c), the mitochondria in cisplatin-treated VC cells (Figures 3A, d) retained the fibrillar fluorescence pattern and strong staining. However, 6 h of cisplatin treatment resulted in the loss of mitochondrial structure and reduced staining in siGal3-11 and siGal3-19 cells (Figures 3A, e and f), as MitoTracker Red dye is washed out of cells and cannot be sequestered once mitochondrial membrane potential is lost. Our results also show that levels of cytosolic cytochrome c in Gal-3 knockdown cells were elevated up to 3.8-fold compared with that in VC cells after cisplatin treatment (Figure 3B). To explore what contributes to Gal-3-associated mitochondrial protection, western blot analysis of Bcl-2 family members was performed and results show that cisplatin treatment increased Bcl-2 expression in Gal-3-expressing VC cells; however, in Gal-3 knockdown cells, Bcl-2 expression was not affected by cisplatin treatment and still remained at the basic level as untreated cells. The expression level of Bcl-XL or Bax between control cells and Gal-3 knockdown transfectants did not show obvious differences (Figure 3C).

Loss of Gal-3 expression enhanced cisplatin-induced calpain activation. Recent studies have demonstrated that activation of calpain could mediate apoptosis.25,26 We examined calpain activation by western blot analysis of its substrate spectrin γII and zymography analysis of its substrate caspase. Spectrin γII is an universally expressed membrane-associated cytoskeletal protein.31 Full-length
spectrin αII can be cleaved into a 150 kD fragment specifically by calpain,
32 or a 120 kD fragment specifically by caspase-3.33 Figure 4A showed that cisplatin treatment
did not change the expression level of either calpain 1 or 2.

In Figure 4B, cisplatin treatment for 12 h resulted in elevated
levels of 150 kD fragments of spectrin in siGal3-11 (3.4-fold)
and siGal3-19 (3.2-fold). Interestingly, 24 h after cisplatin
treatment, 150 kD fragments in Gal-3 knockdown cells
became slightly lower than that in VC cells, it may be possible that 150 kD fragments can be further cleaved by active caspase-3 into 120 kD fragments. In addition, casein zymography showed that 12 h cisplatin treatment resulted in higher level of calpain activity in Gal-3 null VC cells compared with Gal-3 overexpressing clones (Figure 5d). The expression levels of calpain 2 in control cells and Gal-3 overexpressing clones were not changed by cisplatin (Figure 5b).

Calpain activation contributed to the proapoptotic effect of Gal-3 knockdown. Two independent methodologies (specific calpain inhibitor PD150606 and siRNA) were employed to inhibit calpain activation. Figure 6ai indicates that cisplatin-induced calpain activation in Gal-3 knockdown cells was attenuated to 10% by 20 μM PD150606. This dosage of PD150606 also attenuated cisplatin-induced caspase-3 activation (<70% in siGal3-11 and <60% in siGal3-19) and cleavage of PARP (<70% in siGal3-11 and <80% in siGal3-19) in Gal-3 knockdown cells, but had no effect on cytochrome c release or caspase-9 activation (Figure 6aii), suggesting that calpain activation might be a novel mechanism for the proapoptotic effect of Gal-3 knockdown through inducing caspase-3 activation in a mitochondria-independent way. Furthermore, we trans-fected cells with siRNAs targeting calpain 1 or 2 to further understand which isoform exerts the effect. Transfection of calpain 1 siRNA had no effect on apoptosis. Figure 6bi showed the inhibitory efficiency of siRNA targeting calpain 2. Transfection of calpain 2 siRNA attenuated the enhanced caspase-3 activation (<60%) and PARP cleavage (<70% in siGal3-11 and <80% in siGal3-19) in Gal-3 knockdown cells (Figure 6bii), suggesting that calpain 2 activation mediated the proapoptotic effect of Gal-3 knockdown in PC3 cells.

Inhibition of Gal-3 by GCS-100/MCP-enhanced cells’ sensitivity to cisplatin in a calpain-dependent way. To confirm the association of Gal-3 expression with resistance to cisplatin, GCS-100/MCP was used to block the functions of Gal-3. GCS-100/MCP sensitized Gal-3 expressing PC3 cells to cisplatin-induced cell death (Figure 7ai). Compared with cisplatin only, the expression levels of active caspase-3 elevated up to 4.6-fold in cells treated with cisplatin and GCS-100/MCP together (Figure 7aii). These results indicated that GCS-100/MCP may confer cells’ sensitivity to cisplatin-induced apoptosis through blocking Gal-3 functions. Figure 7bi showed that the expression levels of spectrin 150 kD fragments in cells treated with GCS-100/MCP and cisplatin together were up to 3.2-fold higher than cells treated with cisplatin only, this was confirmed with casein zymography (Figure 7bii). In Figure 7c, enhanced cisplatin-induced apoptosis by GCS-100/MCP was attenuated by calpain 2 siRNA, suggesting that the proapoptotic effect of Gal-3 inhibition through GCS-100/MCP was mediated by calpain activation.

Discussion
Prostate cancer is the second leading cause of cancer-related death in Western countries.\textsuperscript{34} The early stages of prostate cancer can be effectively treated by androgen ablation...
therapy. However, most cases of prostate cancer eventually relapse to an androgen refractory state at which chemotherapy is the final choice to slow down the growth of prostate cancer. Unfortunately, chemotherapy is not effective because cancer cells develop resistance to drugs. Therefore, it is imperative to explore novel therapeutic targets to improve the sensitivity of prostate cancer cells to chemotherapy.

Gal-3, a β-galactoside-binding protein, regulates multiple biological functions, including regulating cell proliferation, invasion, tumorigenicity, and apoptosis. It was reported that decreased expression and increased cleavage of Gal-3 are associated with the development and progression of human prostate cancer. Exogenously added recombinant Gal-3 exhibits proapoptotic activity in human T leukemia cells, whereas intracellular Gal-3 imparts resistance to apoptosis in many cancer cells. For example, overexpression of Gal-3 protected human breast cancer cell line BT-549 from apoptosis through inducing cell cycle arrest. Overexpression of Gal-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human bladder carcinoma cells. However, the association of Gal-3 with the resistance to drug-induced apoptosis of prostate cancer cells is not yet well documented. It was reported that Gal-3 overexpression in Gal-3 null LNCaP cells resulted in the acquisition of resistance to anticancer drug-induced apoptosis. On the other hand, PC3 cells express high level of endogenous Gal-3 and are not sensitive to chemotherapeutic agents. The opposite properties between LNCaP and PC3 cells lead us to hypothesize that expression of Gal-3 might partly be responsible for the resistance to drug-induced apoptosis of prostate cancer cells.

To testify our hypothesis, we studied the effect of inhibition of Gal-3 knockdown on cisplatin-induced apoptosis using two approaches: Gal-3 knockdown by siRNA and blockage of Gal-3 functions using GCS-100/MCP. GCS-100/MCP was reported to have inhibitory effects on tumor growth, homotypic and heterotypic cell adhesion of cancer cells, tumor metastasis, and induced apoptosis of cancer cells by acting as an antagonist of Gal-3. As reported, GCS-100/MCP was already used in clinical trials for treating various tumors. Our results showed that Gal-3-expressing cells were resistant to chemotherapeutic drug-induced apoptosis as compared with Gal-3 knockdown cells, indicating that Gal-3 expression may be associated with chemoresistance of PC3 cells and...
inhibition of Gal-3 may render the retrieval of chemosensitivity of prostate cancer cells. Furthermore, we determined that the increased apoptosis mediated by Gal-3 knockdown was due to mitochondrial damage, leading to cytochrome c release and activation of caspase-9. This is consistent with the previous study on LNCaP cells.\textsuperscript{16} The Bcl-2 family consists of both proapoptotic (Bax and Bak) and antiapoptotic (Bcl-2 and Bcl-XL) members.\textsuperscript{38} Here, we report that Gal-3 knockdown alters the expression level of neither Bcl-XL nor Bax. In Gal-3-expressing VC cells, cisplatin treatment resulted in upregulation of Bcl-2, which is the protective factor for mitochondrial integrity. However, in Gal-3 knockdown cells, the expression levels of Bcl-2 after cisplatin treatment remained at the basic level as observed in untreated cells, suggesting that Gal-3 knockdown prevents Bcl-2 upregulation induced by cisplatin and consequent protection of mitochondrial integrity. To confirm the effect of Gal-3 knockdown on apoptosis, GCS-100/MCP was used to block the function of Gal-3, and our results suggest that GCS-100/MCP may enhance cells’ sensitivity to cisplatin through the inhibition of Gal-3.

In addition to the death receptor and mitochondrial apoptotic pathways, increasing evidence indicates the association of calpain activation with apoptosis of prostate cancer cells.\textsuperscript{25,26} Calpain is a family of calcium-dependent proteases that are functionally active as a heterodimer composed of a small regulatory subunit and one large catalytic subunit. Calpain 1 (requires micromolar levels of calcium for activation) and 2 (requires millimolar levels of calcium for activation) are the major members of this family and have been studied most extensively. PC3 cells can express both calpain 1 and 2. It has been reported that calpain activation mediated cisplatin-induced apoptosis in lung cancer cells,\textsuperscript{29} and calpain activation could be triggered in response to alteration of mitochondria-mediated calcium homeostasis.\textsuperscript{27} Studies also showed that cisplatin-induced calpain activation mediated androgen receptor breakdown in apoptotic prostate cancer cells.\textsuperscript{28} Our results demonstrated that non/low Gal-3-expressing cells exhibited higher level of calpain activity than high Gal-3-expressing cells in response to cisplatin treatment (Figures 4 and 5), suggesting that calcium-dependent calpain activation may be a novel mechanism for the proapoptotic effect of Gal-3 knockdown on cisplatin-induced apoptosis in prostate cancer cells. Using specific inhibitor PD150606 and/or siRNAs targeting calpain 1 or 2, we revealed that cisplatin-induced PARP cleavage and caspase-3 activation in Gal-3 knockdown cells were attenuated by PD150606 or calpain 2 siRNA, neither caspase-9 activation nor cytochrome c release was affected, which indicates that calpain activation (specifically calpain 2 activation) mediated proapoptotic effect of Gal-3 knockdown on cisplatin-induced apoptosis in a mitochondria-independent way in prostate cancer cells. This was further confirmed by using GCS-100/MCP. GCS-100/MCP treatment enhanced cisplatin-induced calpain activation through blocking the functions of Gal-3, and the proapoptotic effect of Gal-3 inhibition by GCS-100/MCP was mediated by calpain 2 activation.

Our study suggested that Gal-3 expression contributes, in part, to the chemoresistance of prostate cancer cells, and Gal-3 inhibition by siRNA or GCS-100/MCP could resensitize prostate cancer cells to cisplatin treatment through mitochondrial apoptotic pathway and calpain activation. To conclude, the data suggest a paradigm shift in treating prostate cancer.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure4.png}
\caption{Gal-3 knockdown enhanced cisplatin-induced calpain activation in PC3 cells. Cells were treated with 50 \textmu M cisplatin for indicated times. (A) Western blot analysis showed that cisplatin did not change the expression levels of calpain 1 and 2. (B) Calpain activity as represented by western blot analysis of spectrin 150 kD fragment. Numbers represent the relative intensities of spectrin 150 kD and spectrin 120 kD normalized to \beta-actin. The values of VC cells were set as “1”. (C) Casein zymography to detect calpain activity. Purified recombinant rat calpain 2 was used as the positive control. Numbers represent the intensity of calpain 2. The value of VC cells was set as “1”. (D) Fluorescent image of cytosolic calcium levels (200 \times magnification). Cells were stained with Fluo-4 AM as indicated in Materials and Methods. a and a’, VC; b and b’, siGal3-11; c and c’, siGal3-19. Data are representative of three independent experiments.}
\end{figure}
whereby a combination therapy of a non-toxic polysaccharide Gal-3 antagonist together with a toxic chemotherapeutic agent could serve as a novel therapeutic modality for chemorefractory prostate cancers.

Materials and Methods

**Materials and antibodies.** Monoclonal rat anti-Gal-3 antibody was isolated from the supernatant of hybridoma (catalog number: TIB-166, American Type Culture Collection, Rockville, MD, USA); cisplatin, docetaxel, thiazolyl blue tetrazolium bromide (MTT), mouse anti-β-actin and anti-β-tubulin were purchased from Sigma Chemicals (St. Louis, MO, USA); fluorogenic caspase substrates Ac-DEVD-AMC and Ac-LEHD-AFC, calpain-specific inhibitor PD150606, and mouse anti-Bcl-XL were purchased from Calbiochem (San Diego, CA, USA); MitoTracker red CMXRos and Fluo-4 AM were purchased from Invitrogen (Carlsbad, CA, USA); siRNAs duplex targeting calpain 1, 2 and non-target control siRNA, rabbit anti-caspase-3, rabbit anti-caspase-9, and mouse anti-spectrin αII were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA); mouse anti-PARP (Biomol, Plymouth Meeting, PA, USA); FITC rabbit anti-active caspase-3 (BD Biosciences, San Diego, CA, USA); mouse anti-cytochrome c (Zymed Laboratories, South San Francisco, CA, USA); rabbit anti-Bcl-2, anti-Bax and anti-calpain 2 (Cell Signaling Technology, Beverly, MA, USA).

**Preparation of GCS-100/MCP.** CP was purchased from Sigma Chemicals. Temperature modification of CP was performed as follows: CP solution (1.3%) was autoclaved for 1 h, cooled to room temperature, centrifuged at 10 000 r.p.m. for 10 min. Collected supernatant was precipitated with two volumes of absolute ethanol and frozen at -20°C for a minimum of 2 h. After centrifuging at 10 000 r.p.m. for 10 min again, the supernatant was discarded and pellet was saved. The pellet was resuspended in acetone, filtered, and dried on Whatman filters. MCP

**Figure 5** Gal-3 overexpression reduced cisplatin-induced calpain activation in LNCaP cells. Cells were treated with 50 μM cisplatin for indicated times. (a) The expression levels of Gal-3 in control LNCaP and Gal-3 overexpressing clones. (b) Western blot analysis showed that cisplatin had no effect on the expression level of calpain 2. (c) Calpain activity as represented by western blot analysis of spectrin 150 kD fragment. (d) Casein zymography to detect calpain activity. Purified recombinant rat calpain 2 was used as the positive control. Numbers represent the intensity of calpain 2. The value of VC cells was set as “1”. VC, cells transfected with control vector; #29–11 and #29–23, two Gal-3 overexpressing clones. Data are representative of three independent experiments.

**Figure 6** Calpain activation contributed to the proapoptotic effect of Gal-3 knockdown. Cells were pretreated with 20 μM PD150606 for 30 min and then treated with 50 μM cisplatin for 12 h. (ai) Inhibitory effect of PD150606 on calpain activity. Numbers represent the relative intensity of spectrin 150 kD normalized to β-actin. The values of siGal3-11 and siGal3-19 treated with cisplatin only were set as “1”. (aii) The effect of PD150606 on caspase-3 activation, PARP cleavage, caspase-9 activation, and cytochrome c release. Numbers represent the relative intensities of active caspase-3 and PARP 89 kD normalized to β-actin. The values of siGal3-11 and siGal3-19 treated with cisplatin only were set as “1”. (bi) Downregulation of calpain 2 expression by siRNA transfection. After 24 h of transfection, cells were treated with 50 μM cisplatin for 12 h. (bii) Calpain 2 knockdown attenuated cisplatin-induced caspase-3 activation and PARP cleavage. Cells were treated in the same way as bi. Numbers represent the relative intensities of active caspase-3 and PARP 89 kD normalized to β-tubulin. The values of siGal3-11 and siGal3-19 with sicontrol transfection and cisplatin treatment were set as “1”. Data are representative of three independent experiments.
Galectin-3 inhibition enhanced calpain activity

Y Wang et al

was dissolved in de-ionized distilled water and 0.3% MCP was used as the working concentration.

Cell culture. Human prostate cancer cells PC3 (ATCC CRL-1435) and LNCaP (ATCC CRL-1740) were purchased from the American Type Culture Collection (Manassas, VA, USA). Two Gal-3 knockdown transfectants of PC3 cells named as siGal3-11 and siGal3-19, and one non-target control vector transfectant named as VC were established as described in our previous study.10 Two Gal-3 over-expressing clones of LNCaP cells named as #29-11 and #29-23, and one non-target control vector clone named as VC were kindly provided by Dr. Reuben Lotan (University of Texas MD Anderson cancer center, Houston, Texas, USA). PC3 and LNCaP cells were cultured in Dulbecco's modified Eagle's medium and RPMI 1640 medium, respectively, supplemented with 10% fetal bovine serum. For transfectants, 200 μg/ml G418 (Invitrogen) was added to the culture medium.

Immunofluorescence. Cells were fixed with 4% paraformaldehyde/PBS for 15 min, permeabilized with 0.2% Triton X-100/PBS for 10 min, blocked in 1% bovine serum albumin (BSA)/PBS for 30 min and incubated with rat anti-Gal-3 antibody (1:50) for 1 h, then incubated with Texas red-conjugated anti-rat antibody (1:2000, ICN Biomedicals, Costa Mesa, CA, USA) for 1 h in the dark. Cells were mounted in gelvatol and photographed at the same parameter using Sony DYC-979MD 3CCCD video camera (Tokyo, Japan) connected to an OLYMPUS BX40 microscope (Melville, NY, USA).

Assessment of apoptosis

DNA laddering assay. Cell pellets were lysed with TE/Triton buffer (10 mM Tris (pH 8.0), 0.2% Triton X-100, 1 mM EDTA) on ice for 10 min, centrifuged at 13 000 g for 15 min at 4 °C. This lysis buffer is so mild that it cannot lyse nuclei, so the supernatant only contains the low-molecular weight DNA fragments released from nuclei; therefore, no high-molecular weight DNA is observed. The same amount of supernatant was incubated at 37 °C for 1 h with addition of 70 μg/ml RNase A, incubated at 50 °C for 2 h with addition of 0.5% sodium dodecyl sulfate (SDS) and 500 μg/ml proteinase K, precipitated with ice-cold isopropanol, centrifuged at 13 000 × g for 15 min at 4 °C. DNA pellets were dissolved in TE buffer. DNA solutions were run on a 2% agarose gel containing 100 nM SYTO 60 red fluorescent nucleic acid stain (Invitrogen). The gel was scanned using Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA).

Caspase activity assay. Caspase activity was measured using fluorogenic caspase substrates as described previously.16 Cell pellets were lysed with cell

Figure 7
The blockage of Gal-3 by GCS-100/MCP enhanced cisplatin-induced apoptosis in a calpain-dependent way. (a) Cell viability assay by using MTT. Columns (n = 3), mean; bars, ± S.D. **P < 0.001 compared with cisplatin treatment only. (b) Western blot analysis of active caspase-3. Numbers represent the relative intensity of active caspase-3 normalized to β-actin. The value of control cells was set as “1”. Parental PC3 cells were pretreated with 0.3% MCP for 30 min and then cisplatin for 24 h. (b) Calpain activity as represented by western blot analysis of spectrin 150 kD. Numbers represent the relative intensity of spectrin 150 kD normalized to β-actin. The value of control cells was set as “1”.

Cell viability assay. Cell viability was assessed by MTT as described previously.15 Cell survival of treated cells was represented as the percentage of untreated control cells.

Detection of 89 kD PARP and active caspase-3. Cells pellets were lysed in RIPA buffer (1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 50 mM Tris-HCl (pH 7.5) and 150 mM NaCl) containing protease inhibitors. The resulting cell lysate was analyzed by western blot using anti-PARP antibody and anti-caspase-3 antibody.

DNA content assay by flow cytometry. Briefly, a total of 1 × 106 cells were collected. After washing, cells were fixed with 80% ethanol overnight at −20 °C, washed with PBS, and treated with RNase A (1 mg/ml) for 15 min at 37 °C followed by staining with propidium iodide (50 μg/ml) (Sigma) for 15 min at room temperature. DNA content was analyzed using a Becton Dickinson FACScan (Becton Dickinson, Franklin Lakes, NJ, USA).

Caspase activity assay. Caspase activity was measured using fluorogenic caspase substrates as described previously.16 Cell pellets were lysed with cell

Cell Death and Disease
incubated with secondary antibodies conjugated with IRDye 800 (Rockland Immunochemicals, Gilbertsville, PA, USA) or Alexa Fluor 680 (Invitrogen) for 40 min. After primary and secondary antibodies incubation, membranes were washed four times with TPBS (PBS with 0.1% Tween 20) at 5 min intervals. Immunoblots were visualized using an Odyssey Infrared Imaging System. The quantification of bands intensity was performed using ImageJ software.

Statistical analysis. Data are expressed as mean ± S.D. of three independent experiments and analyzed by one-way ANOVA test using SPSS 14.0 software (SPSS Incorporated, Chicago, IL, USA). P < 0.05 was considered statistically significant.

Conflict of interest
The authors declare no conflict of interest.

Acknowledgements. We thank Vivian Powell for organizing and editing of the manuscript. This work was supported by NIH, National Institutes of Health grant R37CA6120-19 (to A Raz).

1. Eisenberg MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ et al. Bilateral orchectomy with or without fulutamide for metastatic prostate cancer. N Engl J Med 1998; 338: 1036–1042.
2. Inohara H, Akahani S, Raz A. Galectin-3 stimulates cell proliferation. Exp Cell Res 1998; 245: 294–302.
3. O’Driscoll L, Linehan R, Liang YH, Joyce H, Ogleby I, Clynes M. Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP). In: Anticancer Res 2002; 22: 3117–3125.
4. Nangia-Makker P, Nakahara S, Hogan V, Raz A. Galectin-3 in apoptosis, a novel therapeutic target. J Bioenerg Biomembr 2007; 39: 79–84.
5. Miyazaki J, Hokari K, Rato S, Tsuzuki Y, Kawaguchi A, Nagao S. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep 2009; 22: 1307–1312.
6. Turkoz OK, Okuz H, Yurdakul Z, Ozcan D. Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr Pathol 2008; 19: 92–96.
7. Buttery R, Monaghan H, Salter DM, Sethi T. Galectin-3: differential expression between small-cell and non-small-cell lung cancer. Histopathology 2004; 43: 339–344.
8. Iurisci I, Cumashi A, Sherman AA, Tsvetkov YE, Tinari N, Piccolo E et al. Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res 2009; 29: 403–410.
9. Paoz RA, Pilat MJ, Pienta KJ, Wojno K, Raz A, Hogan V et al. Decreased galectin-3 expression in prostate cancer. Prostate 2000; 44: 118–123.
10. Wang Y, Nangia-Makker P, Tait L, Balan V, Hogan V, Pienta KJ et al. Regulation of prostate cancer progression by galectin-3. Am J Pathol 2009; 174: 1515–1523.
11. Ahmed H, Banerjee PP, Vasta GR. Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation. Biochem Biophys Res Commun 2007; 355: 241–246.
12. Ahmed H, Cappello F, Rodolico V, Hogan V, Kanayama HO. Evidence of heavy methylation in the galectin-3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer. Transl Oncol 2009; 2: 146–158.
13. Choi JH, Chun KH, Raz A, Litan R. Inhibition of N-(4-hydroxyphenyl) retinamide-induced apoptosis in breast cancer cells by galectin-3. Cancer Biol Ther 2004; 3: 447–452.
14. Oishi T, Tamochi H, Kigawa J, Kanamori Y, Shimada M, Takahashi M et al. Galectin-3 may contribute to cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer 2007; 17: 1040–1046.
15. Oka N, Nakahara S, Takeyama Y, Fukumori T, Hogan V, Kanauma HO et al. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Res 2005; 65: 7546–7553.
16. Fukumori O, Oka T, Takeyama N, Nangia-Makker P, Elsamary E, Kasai T et al. Galectin-3 regulates mitochondrial stability and apoptotic function in response to anticancer drug in prostate cancer. Cancer Res 2006; 66: 3114–3119.
17. Platt D, Raz A. Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin. J Natl Cancer Inst 1992; 84: 438–442.
18. Inohara H, Raz A. Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconjug J 1994; 11: 527–532.
19. Pienta KJ, Naik H, Akhtar A, Yamazaki K, Replogle TS, Lehr J et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 1995; 87: 348–353.
20. Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 2002; 94: 1854–1862.
21. Jackson CL, Dreaden TM, Theobald LK, Tran NM, Beal TL, Eid M et al. Pectin induces apoptosis in human prostate cancer cells: correlation of apoptotic function with pectin structure. Glycobiology 2007; 17: 805–819.
22. Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res 2005; 65: 8350–8358.

23. Nomura T, Yamasaki M, Nomura Y, Mimata H. Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol Rep 2005; 14: 993–997.

24. Strasser A, O'Connor L, Dixt VM. Apoptosis signaling. Annu Rev Biochem 2000; 69: 217–245.

25. Lien YC, Kung HN, Lu KS, Jeng CJ, Chau YP. Involvement of endoplasmic reticulum stress and activation of MAP kinases in beta-lapachone-induced human prostate cancer cell apoptosis. Histol Histopathol 2008; 23: 1299–1308.

26. St John Floyd Jr M, Teahan SJ, Watson RW. Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines. Prostate Cancer Prostatic Dis 2009; 12: 25–33.

27. Vosler PS, Sun D, Wang S, Gao Y, Kintner DB, Signore AP et al. Calcium dysregulation induces apoptosis-inducing factor release: cross-talk between PARP-1- and calpain-signaling pathways. Exp Neurol 2009; 218: 213–220.

28. Yang H, Murthy S, Sarkar FH, Sheng S, Reddy GP, Dou GP. Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells. J Cell Physiol 2008; 217: 569–576.

29. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly (ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994; 371: 346–347.

30. Oliver FJ, la Rubia G, Rolli V, Ruz-Ruiz MC, de Murcia G, Murcia JM. Importance of poly (ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 1998; 273: 3533–3539.

31. Bennett V, Gilligan DM. The spectrin-based membrane skeleton and micron-scale organization of the plasma membrane. Annu Rev Cell Biol 1993; 9: 27–66.

32. Yokota M, Saito TC, Kambatli H, Tabuchi S, Satokata I, Watanabe T. Calpain induces proteolysis of neuronal cytoskeleton in ischemic gerbil forebrain. Brain Res 2003; 984: 122–132.

33. Nath R, Huggins M, Giantz SB, Morrow JS, McGinnis K, Nadimpalli R et al. Development and characterization of antibodies specific to caspase-3-produced alpha II-spectrin 120kDa breakdown product: marker for neuronal apoptosis. Neurochem Int 2000; 37: 351–361.

34. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007; 57: 43–66.

35. Fukumori T, Takenaka Y, Yoshii T, Kim HR, Hogan V, Inohara H et al. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res 2003; 63: 8302–8311.

36. Lin HM, Moon BK, Yu F, Kim HR. Galectin-3 mediates genistein-induced G2/M arrest and inhibits apoptosis. Carcinogenesis 2003; 24: 1941–1945.

37. Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res 2005; 65: 8350–8358.

38. Chao DT, Korsmeyer SJ. Bcl-2 family: regulators of cell death. Annu Rev Immunol 1998; 16: 395–419.

39. Liu L, Xing D, Chen WR, Chen T, Pei Y, Gao X. Calpain-mediated pathway dominates cisplatin-induced apoptosis in human lung adenocarcinoma cells as determined by real-time single cell analysis. Int J Cancer 2008; 122: 2210–2222.

40. Raser KJ, Posner A, Wang KK. Casein zymography: a method to study mu-calpain, m-calpain, and their inhibitory agents. Arch Biochem Biophys 1996; 319: 211–216.